TRAX is First Tracks Biotherapeutics, Inc. (Healthcare) — a non-dividend-paying stock. Trading at $40.70. Market cap: $1.52B.
Stock snapshot
| Price | $40.70 |
| Market cap | $1.52B |
| Sector | Healthcare |
| Exchange | NMS |
| Pays dividend | No |
About TRAX
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
Related non-dividend companies
Other non-dividend stocks investors research alongside TRAX. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is TRAX's current stock price?
TRAX (First Tracks Biotherapeutics, Inc.) is currently trading at $40.70.
Does TRAX pay a dividend?
TRAX (First Tracks Biotherapeutics, Inc.) does not currently pay a regular dividend.
Track TRAX in DiviDrip
Add TRAX to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search TRAX and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-04. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.